Manjulika Das. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Anaplastic Lymphoma KinaseAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/enzymologyCarcinoma, Non-Small-Cell Lung/mortalityCarcinoma, Non-Small-Cell Lung/pathologyClinical Trials, Phase II as TopicDisease ProgressionDisease-Free SurvivalHumansLung Neoplasms/drug therapyLung Neoplasms/enzymologyLung Neoplasms/mortalityLung Neoplasms/pathologyOrganophosphorus Compounds/adverse effectsOrganophosphorus Compounds/therapeutic useProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/therapeutic usePyrimidines/adverse effectsPyrimidines/therapeutic useRandomized Controlled Trials as TopicReceptor Protein-Tyrosine Kinases/antagonists & inhibitorsReceptor Protein-Tyrosine Kinases/metabolismTime FactorsTreatment Outcome
Substances： See more » Antineoplastic AgentsOrganophosphorus CompoundsProtein Kinase InhibitorsPyrimidinesALK protein, humanAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine Kinasesbrigatinib
Year: 2017 PMID： 28506557 DOI： 10.1016/S1470-2045(17)30342-X
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316